Navigation Links
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Date:12/4/2007

estimated 8,000 to 10,000 people in North America and Western Europe.(5) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's.(6) Approximately ten percent of all patients first develop symptoms at 21 years of age or younger.(3) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years.(2) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis.(2,6)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS).(7,8,9,10) In patients with thrombosis of unknown origin, PNH may be an underlying cause.(3,11) Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantation -- a procedure that carries considerable mortality risk.(3,11)

About Soliris(R)

Soliris (eculizumab) was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commission (EC) also approved the use of Soliris (eculizumab) for the treatment of patients with PNH. Soliris is the first therapy approved in Europe for the treatment of PNH and was the first medicinal product to receive EU approval under the EMEA Accelerated Assessment Procedure.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris sh
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... five studies sponsored,by Ortho Biotech Products, L.P. will ... Spring Clinical Meetings from April 2 - 6, ... The data include studies that compare drug utilization ... (DARB), evaluate medical costs,related to chronic kidney disease ...
... FOSRENOL(R) and Resources ... Enhanced Hyperphosphatemia Management, PHILADELPHIA, April 3, 2008 ... of On Track,an innovative program designed to improve adherence ... 5 patients with,hyperphosphatemia (elevated levels of phosphorus in the ...
Cached Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 2Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 3Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 4Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 5Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 6Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 7Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 8
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... Medarex, Inc.,(Nasdaq: MEDX ) announced today its financial ... gain of $151.8 million, or $1.19 per share, from Medarex,s,sale ... 2008, Medarex,s,net income for the quarter ended March 31, 2008, ... net income of $110.3 million, or $0.88,per share for the ...
... MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, ... over the previous eight,months regarding the formation of ... in these negotiations where final written terms have ... to the Company,s very first,product acquisition. It should ...
... 12 The American Veterinary,Medical Association (AVMA) has reinforced ... horses and other equines by approving a,new policy on ... by the AVMA Executive Board on April 12, 2008,states ... AVMA opposes the,use of double-deck trailers to transport equines. ...
... The Myanmar Relief Fund,( http://www.MyanmarReliefFund.org ) is a ... the know-how to get aid in and directly ... are treating the,injured, and a myriad of supplies ... is a coalition of private American and Myanmar,citizens ...
... G.,Komen Pittsburgh Race for the Cure(R) are as follows:, 1st Place ... 15:14 Female: Kelly Knickelbein, Pittsburgh, Pa., 19:19, ... Burnett, 16:02 Female: Anna Beck, Washington, Pa., ... Charlie Ban, Pittsburgh, Pa., 16:13 Female: Jessica ...
... Better Care,Better Regulation, WASHINGTON, May 11 ... ManorCare nursing homes in sixteen states,across the nation ... a call to,action from quality care advocates. The ... Managing Director David Rubenstein to demand better,care. In ...
Cached Medicine News:Health News:Medarex Announces 2008 First Quarter Financial Results 2Health News:Medarex Announces 2008 First Quarter Financial Results 3Health News:Medarex Announces 2008 First Quarter Financial Results 4Health News:Medarex Announces 2008 First Quarter Financial Results 5Health News:Medarex Announces 2008 First Quarter Financial Results 6Health News:Medarex Announces 2008 First Quarter Financial Results 7Health News:Medarex Announces 2008 First Quarter Financial Results 8Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2Health News:AVMA Opposes Use of Double-Deck Trailers for Transporting Horses and Other Equines 2Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Advocates Make Mother's Day Push for Quality Care 2
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
... and Increase Staff Protection With Medline's Sterile Suction ... Fr, 16 Fr and 18 Fr), ,Medline ... the U.S. We manufacture most of our suction ... exceeds our customers' expectations. We manufacture, supply and ...
... are available in two tip ... tip with staggered eyes, and ... types of catheter valve options, ... fingertip control with virtually no ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
Medicine Products: